No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KBR240517P67500
- 1.20
- +0.08+7.14%
15min DelayClose May 10 16:00 ET
1.20High1.20Low
1.20Open1.12Pre Close1 Volume564 Open Interest67.50Strike Price120.00Turnover46.93%IV-1.80%PremiumMay 17, 2024Expiry Date1.00Intrinsic Value100Multiplier6DDays to Expiry0.20Time Value100Contract SizeAmericanOptions Type-0.5761Delta0.0936Gamma30.23Leverage Ratio-0.1238Theta-0.0066Rho-17.41Eff Leverage0.0350Vega
Intraday
- 5D
- 1D
News
KBR Inc Is Maintained at Buy by Stifel
KBR Inc Is Maintained at Buy by Stifel
Express News | KBR Inc : Stifel Raises Target Price to $84 From $83
Express News | KBR Inc: Sees 2027 Long Term Targets Revenues $11.5 Bln+
Express News | KBR Inc: Expects to Exceed $1.15 Bln Adj. Ebitda by 2027
Press Release: KBR Showcases Enduring Growth, Confident Outlook at 2024 Investor Event
KBR Showcases Enduring Growth, Confident Outlook at 2024 Investor Event PR Newswire HOUSTON, May 8, 2024 Expects to Exceed $1.15B Adj. EBITDA(1) by 2027 Double digit profit and cash flow growth H
KBR Showcases Enduring Growth, Confident Outlook at 2024 Investor Event
Expects to Exceed $1.15B Adj. EBITDA1 by 2027Double digit profit and cash flow growth HOUSTON, May 8, 2024 /PRNewswire/ -- KBR, Inc. (NYSE: KBR) today hosted an Investor Day event at the New York Sto
Comments
KBR's revenue growth could be seen as a positive sign, despite potential sacrifice of current earnings per share. Future earnings are crucial for shareholders. Despite slower share price gains, the business may continue to perform well.
Those Who Invested in KBR (NYSE:KBR) Five Years Ago Are up 238%Given the upward trend and increased efficiency in KBR's return on capital employed, it appears to show promise. Considering the outstanding shareholder returns over the last five years, it's advisable for investors to explore if these trends will continue.
Sizable insider selling at KBR creating investor caution. Lack of insider buying combined with substantial selling seen as red flag. 1.0% insider ownership doesn't fully dispel concerns.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $ON Semiconductor(ON.US$ - up 3.0%
2. $JPMorgan(JPM.US$ - up 1.8%
3. $Uber Technologies(UBER.US$ - up 1.6%
4. $KBR Inc(KBR.US$ - up 0.8%
5. $Wells Fargo & Co(WFC.US$ - up 0.7%
6. $James Hardie Industries(JHX.US$ - up 0.5%
7. $Celsius Holdings(CELH.US$ - up 0.5%
8....
Gap Ups
1. $ON Semiconductor(ON.US$ - up 3.0%
2. $JPMorgan(JPM.US$ - up 1.8%
3. $Uber Technologies(UBER.US$ - up 1.6%
4. $KBR Inc(KBR.US$ - up 0.8%
5. $Wells Fargo & Co(WFC.US$ - up 0.7%
6. $James Hardie Industries(JHX.US$ - up 0.5%
7. $Celsius Holdings(CELH.US$ - up 0.5%
8....
+9
11
Gainers:
• $Rocket Pharmaceuticals(RCKT.US$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose(GOOS.US$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
• $Rocket Pharmaceuticals(RCKT.US$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose(GOOS.US$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
12
Read more